Certain 1,4-Disubstituted Aromatic Piperidines and Piperazines with Extreme Selectivity for the Dopamine D4 Receptor Interact with a Common Receptor Microdomain
暂无分享,去创建一个
Peter Gmeiner | Sandhya Kortagere | Harel Weinstein | H. Weinstein | S. Kortagere | P. Gmeiner | J. Schetz | John A Schetz
[1] D. Sibley,et al. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. , 2000, Molecular pharmacology.
[2] C. Gallen,et al. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial , 2004, Biological Psychiatry.
[3] D. Donnelly-roberts,et al. Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning. , 2004, Journal of medicinal chemistry.
[4] B. Sommer,et al. NGD 94-1 as an agonist at human recombinant dopamine D4.4 receptors expressed in HEK293 cells. , 1999, European journal of pharmacology.
[5] J. Javitch,et al. Mechanisms of inverse agonism of antipsychotic drugs at the D2 dopamine receptor: use of a mutant D2 dopamine receptor that adopts the activated conformation , 2001, Journal of neurochemistry.
[6] Harel Weinstein,et al. Three-dimensional representations of G protein-coupled receptor structures and mechanisms. , 2002, Methods in enzymology.
[7] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[8] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[9] J. Ballesteros,et al. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.
[10] D. B. Duignan,et al. Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist. , 1998, Bioorganic & medicinal chemistry letters.
[11] H. Weinstein,et al. Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. , 2003, Molecular Pharmacology.
[12] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[13] J. Ballesteros,et al. Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. , 1999, Molecular pharmacology.
[14] A. Getson,et al. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. , 1997, Archives of general psychiatry.
[15] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.
[16] B. Sommer,et al. The agonist activities of the putative antipsychotic agents, L‐745,870 and U‐101958 in HEK293 cells expressing the human dopamine D4.4 receptor , 1998, British journal of pharmacology.
[17] David R. Sibley,et al. Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.
[18] H. Akil,et al. Site-directed mutagenesis of the human dopamine D2 receptor. , 1992, European journal of pharmacology.
[19] Robert P. Millar,et al. Functional Microdomains in G-protein-coupled Receptors , 1998, The Journal of Biological Chemistry.
[20] M. Piercey,et al. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist. , 1996, The Journal of pharmacology and experimental therapeutics.
[21] H. V. Van Tol,et al. The dopamine D(4) receptor: one decade of research. , 2000, European journal of pharmacology.
[22] M. Low,et al. The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder , 2004, Molecular Psychiatry.
[23] J. Ballesteros,et al. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.
[24] J. Lusher,et al. Dopamine D4 receptor gene (DRD4) is associated with Novelty Seeking (NS) and substance abuse: the saga continues . . . , 2001, Molecular Psychiatry.
[25] T. Kikuchi,et al. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. , 1988, Life sciences.
[26] P. Leeson,et al. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. , 1997, The Journal of pharmacology and experimental therapeutics.
[27] J. Nobrega,et al. Dopamine D2‐like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline , 1997, Synapse.
[28] Philip Seeman,et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.
[29] G A Petsko,et al. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.
[30] P. Gmeiner,et al. Rationally based efficacy tuning of selective dopamine d4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213). , 2001, Journal of medicinal chemistry.
[31] S. Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.
[32] H. Weinstein,et al. Conformational Memories and the Exploration of Biologically Relevant Peptide Conformations: An Illustration for the Gonadotropin-Releasing Hormone , 1996 .
[33] F. Diederich,et al. Interactions with aromatic rings in chemical and biological recognition. , 2003, Angewandte Chemie.
[34] M. Karplus,et al. Evaluation of comparative protein modeling by MODELLER , 1995, Proteins.
[35] J. Feldon,et al. FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia , 2004, Psychopharmacology.
[36] D. Helmeste,et al. Dopamine D4 receptors. , 2000, Japanese journal of pharmacology.
[37] Y. Sagara,et al. The Activation of Dopamine D4 Receptors Inhibits Oxidative Stress-Induced Nerve Cell Death , 2001, The Journal of Neuroscience.
[38] P. Seeman,et al. Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors , 1997, Neuropsychopharmacology.
[39] T. Heffner,et al. Substituted [(4-phenylpiperazinyl)-methyl]benzamides: selective dopamine D4 agonists. , 1997, Journal of medicinal chemistry.
[40] P. Seeman,et al. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata , 1993, Synapse.